Literature DB >> 27240600

Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy.

Youssef Bennani Smires1, Gérard Victor2, David Ribes3, Matthieu Berry1,4, Thomas Cognet1,2,4, Simon Méjean1,2,4,5, Antoine Huart3, Murielle Roussel6, Antoine Petermann7, Jérôme Roncalli1,8, Didier Carrié1,4,8, Hervé Rousseau5,7, Isabelle Berry2,4,5, Dominique Chauveau3,5, Michel Galinier1,4,5, Olivier Lairez9,10,11,12.   

Abstract

This study sought to phenotype patients over 65 years old with heart failure and preserved ejection fraction (HFpEF) using clinical available comprehensive cardiovascular imaging modalities. Forty-nine patients with HFpEF and without coronary artery disease underwent clinical evaluation, electrocardiography, echocardiography, cardiac magnetic resonance (CMR) and 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy (99mTc-DPD). The mean population age was 76 ± 8 years. Most of the patients (53 %) were NYHA class II. Mean NT-Pro-NBNP level was 1961 ± 2372 pg/ml. CMR exhibited a hypertrophic cardiomyopathy or infiltrative pattern in 3 (6 %) and 15 (31 %) patients, respectively. In the latter subgroup, 99mTc-DPD was suggestive of transthyretin-related cardiac amyloidosis for nine (18 %) patients, while AL amyloidosis was proven in five patients (10 %) by extracardiac (n = 3, 6 %) or endomyocardial (n = 2, 4 %) biopsies-one patient declined tissue biopsy. Compared to patients with unspecified cardiomyopathy (n = 31), patients with amyloid cardiomyopathy (n = 15 or n = 14/proven) had less hypertension, lower systolic blood pressure and higher NT-pro BNP level. Their electrocardiogram showed lowest QRS voltage and longer QRS duration. Left ventricular (LV) pattern was characterized by a more pronounced LV hypertrophy, a smaller ejection fraction and a decrease of global longitudinal strain associated with an increase of longitudinal strain apical-to-basal ratio. In patients over 65 years, HFpEF is a heterogeneous syndrome with at least a 29 % prevalence of amyloid cardiomyopathy. Combined CMR and 99mTc-DPD are helpful imaging tools for accurate phenotyping of patients amenable to histopathological diagnosis or genetic testing, and should be considered for proper management of this population. Further longitudinal investigations are needed to better clarify these preliminary results.

Entities:  

Keywords:  Amyloid cardiomyopathy; Cardiac amyloidosis; Cardiac imaging; Heart failure with preserved ejection fraction

Mesh:

Substances:

Year:  2016        PMID: 27240600     DOI: 10.1007/s10554-016-0915-z

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  27 in total

1.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

2.  Phenomapping for novel classification of heart failure with preserved ejection fraction.

Authors:  Sanjiv J Shah; Daniel H Katz; Senthil Selvaraj; Michael A Burke; Clyde W Yancy; Mihai Gheorghiade; Robert O Bonow; Chiang-Ching Huang; Rahul C Deo
Journal:  Circulation       Date:  2014-11-14       Impact factor: 29.690

3.  Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.

Authors:  Imran S Syed; James F Glockner; Dali Feng; Philip A Araoz; Matthew W Martinez; William D Edwards; Morie A Gertz; Angela Dispenzieri; Jae K Oh; Diego Bellavia; A Jamil Tajik; Martha Grogan
Journal:  JACC Cardiovasc Imaging       Date:  2010-02

4.  Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis.

Authors:  David F Hutt; Anne-Marie Quigley; Joanne Page; Margaret L Hall; Maria Burniston; Dorothea Gopaul; Thirusha Lane; Carol J Whelan; Helen J Lachmann; Julian D Gillmore; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-06-16       Impact factor: 6.875

5.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.

Authors:  Esther González-López; Maria Gallego-Delgado; Gonzalo Guzzo-Merello; F Javier de Haro-Del Moral; Marta Cobo-Marcos; Carolina Robles; Belén Bornstein; Clara Salas; Enrique Lara-Pezzi; Luis Alonso-Pulpon; Pablo Garcia-Pavia
Journal:  Eur Heart J       Date:  2015-07-28       Impact factor: 29.983

6.  Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.

Authors:  Selma F Mohammed; Sultan A Mirzoyev; William D Edwards; Ahmet Dogan; Donna R Grogan; Shannon M Dunlay; Veronique L Roger; Morie A Gertz; Angela Dispenzieri; Steven R Zeldenrust; Margaret M Redfield
Journal:  JACC Heart Fail       Date:  2014-04       Impact factor: 12.035

7.  Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases.

Authors:  R A Kyle; P R Greipp; W M O'Fallon
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

Review 8.  The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease.

Authors:  Gianluca Di Bella; Fausto Pizzino; Fabio Minutoli; Concetta Zito; Rocco Donato; Giuseppe Dattilo; Giuseppe Oreto; Sergio Baldari; Giuseppe Vita; Bijoy K Khandheria; Scipione Carerj
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-09-04       Impact factor: 6.875

9.  Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation.

Authors:  J D Carroll; W H Gaasch; K P McAdam
Journal:  Am J Cardiol       Date:  1982-01       Impact factor: 2.778

10.  A status report on RNAi therapeutics.

Authors:  Akshay K Vaishnaw; Jared Gollob; Christina Gamba-Vitalo; Renta Hutabarat; Dinah Sah; Rachel Meyers; Tony de Fougerolles; John Maraganore
Journal:  Silence       Date:  2010-07-08
View more
  21 in total

1.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.

Authors:  Sharmila Dorbala; Yukio Ando; Sabahat Bokhari; Angela Dispenzieri; Rodney H Falk; Victor A Ferrari; Marianna Fontana; Olivier Gheysens; Julian D Gillmore; Andor W J M Glaudemans; Mazen A Hanna; Bouke P C Hazenberg; Arnt V Kristen; Raymond Y Kwong; Mathew S Maurer; Giampaolo Merlini; Edward J Miller; James C Moon; Venkatesh L Murthy; C Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Sanjiv J Shah; Riemer H J A Slart; Hein J Verberne; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2019-12       Impact factor: 5.952

2.  State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis.

Authors:  Vasvi Singh; Rodney Falk; Marcelo F Di Carli; Marie Kijewski; Claudio Rapezzi; Sharmila Dorbala
Journal:  J Nucl Cardiol       Date:  2018-12-19       Impact factor: 5.952

Review 3.  How to Image Cardiac Amyloidosis: A Practical Approach.

Authors:  Sharmila Dorbala; Sarah Cuddy; Rodney H Falk
Journal:  JACC Cardiovasc Imaging       Date:  2019-10-11

Review 4.  Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction.

Authors:  Wengen Chen; Van-Khue Ton; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2018-03-08       Impact factor: 2.931

5.  Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis.

Authors:  Giorgio Treglia; Andor W J M Glaudemans; Francesco Bertagna; Bouke P C Hazenberg; Paola A Erba; Raffaele Giubbini; Luca Ceriani; John O Prior; Luca Giovanella; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-23       Impact factor: 9.236

6.  Yield of bone scintigraphy screening for transthyretin-related cardiac amyloidosis in different conditions: Methodological issues and clinical implications.

Authors:  Giacomo Tini; Eugenio Sessarego; Stefano Benenati; Pier Filippo Vianello; Beatrice Musumeci; Camillo Autore; Marco Canepa
Journal:  Eur J Clin Invest       Date:  2021-08-22       Impact factor: 5.722

7.  Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience.

Authors:  Omar K Siddiqi; Yuliya Y Mints; John L Berk; Lawreen Connors; Gheorghe Doros; Deepa M Gopal; Shivangi Kataria; Graham Lohrmann; Alexandra R Pipilas; Frederick L Ruberg
Journal:  Amyloid       Date:  2022-01-27       Impact factor: 6.571

Review 8.  Amyloidosis in Heart Failure.

Authors:  Sandra Ihne; Caroline Morbach; Laura Obici; Giovanni Palladini; Stefan Störk
Journal:  Curr Heart Fail Rep       Date:  2019-12

9.  Cases from a busy nuclear cardiology laboratory: Potential pitfalls in the interpretation of cardiac scintigraphy for ATTR cardiac amyloidosis.

Authors:  Ramsey M Wehbe; Preeti Kansal; Thomas A Holly
Journal:  J Nucl Cardiol       Date:  2020-05-07       Impact factor: 5.952

Review 10.  Nuclear Imaging for Cardiac Amyloidosis: Bone Scan, SPECT/CT, and Amyloid-Targeting PET.

Authors:  Jin Chul Paeng; Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2021-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.